Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States for $550 million.
It comprises a balance of mature and growth brands, Aczone, Tazorac, Azelex and Cordran Tape, as well as Seysara.
Seysara is a new, innovative first in class tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of moderate to severe acne vulgaris, in patients 9 years of age and older.
The FDA approval of Seysara is anticipated in Q4 2018.
“This is a transformational deal for Almirall,” said CEO Peter Guenter.
“It will reinforce and consolidate our position in the world’s largest dermatology market and is a well-balanced portfolio of mature and growth brands with a major launch opportunity of an innovative New Chemical Entity (NCE).
“It is perfectly complementary to our existing platform and will be immediately accretive to our earnings.
“It offers us medium to long term top and bottom line growth opportunities. Moreover, it will allow for an expanded platform to launch KX2-391, which has the potential to become a new standard of care in actinic keratosis”